According to Tonghua Dongbao, the company's human insulin raw material product recently received approval from the National Drug Regulatory Authority of Pakistan, marking a new step forward in its internationalization strategy as the product can now be officially supplied to the Pakistani market.
This approval was achieved by the company, as a supplier of human insulin raw materials, by supporting overseas clients in completing the registration and market approval of their formulation products in Pakistan, demonstrating the overseas competitiveness of the company's raw material products. With over two decades of experience in the insulin field, the company has built a mature and stable large-scale raw material production system and a full life-cycle quality control system, enabling it to provide reliable and continuous raw material supplies to its global partners.
Pakistan bears one of the heaviest burdens of diabetes globally. Data from the International Diabetes Federation shows that in 2024, Pakistan had approximately 34.53 million adults aged 20 to 79 with diabetes, representing a prevalence rate of 26.5%, ranking among the highest in the world. This number is projected to climb to 70.2 million by 2050, potentially making Pakistan the third-largest country in the world with diabetes. Meanwhile, approximately 26.9% of adults in Pakistan with diabetes remain undiagnosed, corresponding to about 9.3 million people, who face various risks of complications. This large patient base and the resulting gap in treatment options create an urgent and continuously growing demand for high-quality, affordable insulin products in the country.
This approval not only opens up supply chain channels for the company in the Pakistani market but will also provide crucial assurance for local patients to access safe and effective insulin therapy. In its overseas product pipeline, the company has built a complete portfolio covering human insulin, insulin analogs, and GLP-1 receptor agonists, enabling it to provide high-quality product solutions tailored to different market needs.
Looking ahead, the International Diabetes Federation projects that the number of people with diabetes worldwide will exceed 853 million by 2050, creating a huge market demand that provides ample opportunities for high-quality insulin suppliers. Dongbao Pharmaceutical will continue to deepen its international registration strategy, accelerate the market launch of its APIs and formulations in more countries and regions, and participate in the construction of a global diabetes treatment system.
Tonghua Dongbao Pharmaceutical Co., Ltd., established in 1985 and listed on the Shanghai Stock Exchange in 1994, is a well-known domestic pharmaceutical company integrating drug research and development, production, and sales. The company focuses on the field of diabetes treatment, possessing a product system centered on insulin, including human insulin, glargine insulin, aspart insulin, and GLP-1RA liraglutide injection, and continuously expanding the indications for its pipeline products. In the future, the company will continue to adhere to independent innovation, accelerate the transformation of technological achievements, and strive to become an explorer and leader in innovative pharmaceutical research and development in the field of endocrinology.

https://mp.weixin.qq.com/s/JPIGKE20CRVL1xdURmwMww